Design and conduct considerations for first-in-human trials of biologics

Visit for more related articles at Journal of Cardiovascular Medicine and Therapy

Abstract

Current drug development research is generating many new approaches for using biologics in diverse therapeutic areas. However, the TeGenero disaster spurred a fundamental rethinking by regulators. Special rules have been developed for pre-clinical and first-in-human clinical trials. However, due to the complexity of these drugs, the severity of their potential side-effects, and their therapeutical areas, it is often difficult to plan first-in-human clinical trials. Defining relevant animal models for in vivo pre-clinical studies, calculating the initial start dose and maximal dose in human trials, and implementing appropriate safety-monitoring assessments remain a challenge. These factors should be considered in planning any first-in-human clinical trials.

Select your language of interest to view the total content in your interested language

Viewing options

Flyer image

Share This Article